Patients with specific kidney conditions can look forward to improved treatment protocols. The Kidney Disease Improving Global Outcomes (KDIGO) group has issued an update to its clinical practice guidelines, focusing on two types of glomerular disease: immunoglobulin A nephropathy (IgAN) and immunoglobulin A vasculitis (IgAV). The updated information was disseminated by nephrologists at the University of Cincinnati, as reported by MedCentral.
An autoimmune disease, IgAN, also known as Berger’s disease, is manifested through the accumulation of IgA immune proteins in the kidneys, causing inflammation and potential kidney failure. IgAV, however, mainly strikes children, distinguished by the IgA-driven swelling and bleeding of small blood vessels, involving skin, joints, and notably, the kidneys. It’s often set off by an infection.
The latest from KDIGO builds on their 2021 guide. New treatment insight provides a roadmap for risk assessment, diagnosis, general supportive care, and tailored drug therapies. As outlined by MedCentral, it also delves into the nuances of maternity, pediatrics, and handling aggressive disease progression…